On the interactions between nucleotide binding domains and membrane spanning domains in cystic fibrosis transmembrane regulator: A molecular dynamic study

Biochimie

Volumn 111, Issue , 2015, Pages 19-29

  Belmonte, Luca ^a,b   Moran, Oscar ^a  

^a CNR   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

CFTR; Cystic fibrosis; Molecular dynamics; Nucleotide binding domains; F508 G551D

Indexed keywords

ABC TRANSPORTER; ARGININE; ASPARTIC ACID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTAMINE; GLYCINE; MEMBRANE PROTEIN; MEMBRANE SPANNING DOMAIN; NUCLEOTIDE BINDING DOMAIN; SERINE; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN;

ARTICLE; CHANNEL GATING; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENERGY; HUMAN; HYDROGEN BOND; MOLECULAR DYNAMICS; NUCLEOTIDE BINDING SITE; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SURFACE PROPERTY; CHEMISTRY; GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE;

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84922309675     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2015.01.010     Document Type: Article

References (55)

1. N.H. Awayn, M.F. Rosenberg, A.B. Kamis, L.A. Aleksandrov, J.R. Riordan, and R.C. Ford Crystallographic and single-particle analyses of native- and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Biochem. Soc. Trans. 33 2005 996 999
2. M.F. Rosenberg, A.B. Kamis, L.A. Aleksandrov, R.C. Ford, and J.R. Riordan Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR) J. Biol. Chem. 279 2004 39051 39057
3. M.F. Rosenberg, L.P. O'Ryan, G. Hughes, Z. Zhao, L.A. Aleksandrov, J.R. Riordan, and R.C. Ford The cystic fibrosis transmembrane conductance regulator (CFTR): three-dimensional structure and localization of a channel gate J. Biol. Chem. 286 2011 42647 42654
4. L. Zhang, L.A. Aleksandrov, Z. Zhao, J.R. Birtley, J.R. Riordan, and R.C. Ford Architecture of the cystic fibrosis transmembrane conductance regulator protein and structural changes associated with phosphorylation and nucleotide binding J. Struct. Biol. 167 2009 242 251
5. C. Marasini, L. Galeno, and O. Moran A SAXS-based ensemble model of the native and phosphorylated regulatory domain of the CFTR Cell. Mol. Life Sci. 70 2013 923 933
6. E. Galfrè, L. Galeno, and O. Moran A potentiator induces conformational changes on the recombinant CFTR nucleotide binding domains in solution Cell. Mol. Life Sci. 69 2012 3701 3713
7. L. Galeno, E. Galfrè, and O. Moran Small-angle X-ray scattering study of the ATP modulation of the structural features of the nucleotide binding domains of the CFTR in solution Eur. Biophys. J. 40 2011 811 824
8. S. Atwell, C.G. Brouillette, K. Conners, S. Emtage, T. Gheyi, W.B. Guggino, J. Hendle, J.F. Hunt, H.A. Lewis, F. Lu, I.I. Protasevich, L.A. Rodgers, R. Romero, S.R. Wasserman, P.C. Weber, D. Wetmore, F.F. Zhang, and X. Zhao Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant Protein Eng. Des. Sel. 23 2010 375 384
9. H.A. Lewis, X. Zhao, C. Wang, J.M. Sauder, I. Rooney, B.W. Noland, D. Lorimer, M.C. Kearins, K. Conners, B. Condon, P.C. Maloney, W.B. Guggino, J.F. Hunt, and S. Emtage Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure J. Biol. Chem. 280 2005 1346 1353
10. H.A. Lewis, S.G. Buchanan, S.K. Burley, K. Conners, M. Dickey, M. Dorwart, R. Fowler, X. Gao, W.B. Guggino, W.A. Hendrickson, J.F. Hunt, M.C. Kearins, D. Lorimer, P.C. Maloney, K.W. Post, K.R. Rajashankar, M.E. Rutter, J.M. Sauder, S. Shriver, P.H. Thibodeau, P.J. Thomas, M. Zhang, X. Zhao, and S. Emtage Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator EMBO J. 23 2004 282 293
11. N. Odolczyk, and P. Zielenkiewicz Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies Int. J. Biochem. Cell. Biol. 52C 2014 39 46
12. J.P. Mornon, P. Lehn, and I. Callebaut Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces Cell. Mol. Life Sci. 65 2008 2594 2612
13. J. Mornon, P. Lehn, and I. Callebaut Molecular models of the open and closed states of the whole human CFTR protein Cell. Mol. Life Sci. 66 2009 3469 3486
14. W. Dalemans, P. Barbry, G. Champigny, S. Jallat, K. Dott, D. Dreyer, R.G. Crystal, A. Pavirani, J.P. Lecocq, and M. Lazdunski Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation Nature 354 1991 526 528
15. C.M. Haws, I.B. Nepomuceno, M.E. Krouse, H. Wakelee, T. Law, Y. Xia, H. Nguyen, and J.J. Wine Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines Am. J. Physiol. 270 1996 C1544 C1555
16. O. Moran On the structural organization of the intracellular domains of CFTR Int. J. Biochem. Cell. Biol. 52C 2014 7 14
17. D.P. Rich, R.J. Gregory, M.P. Anderson, P. Manavalan, A.E. Smith, and M.J. Welsh Effect of deleting the R domain on CFTR-generated chloride channels Science 253 1991 205 207
18. J. Ma, J. Zhao, M.L. Drumm, J. Xie, and P.B. Davis Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel J. Biol. Chem. 272 1997 28133 28141
19. S.G. Bompadre, T. Ai, J.H. Cho, X. Wang, Y. Sohma, M. Li, and T.C. Hwang CFTR gating I: characterization of the ATP-dependent gating of a phosphorylation-independent CFTR channel (DeltaR-CFTR) J. Gen. Physiol. 125 2005 361 375 Epub 2005 Mar 14
20. S.G. Bompadre, J.H. Cho, X. Wang, X. Zou, Y. Sohma, M. Li, and T.C. Hwang CFTR gating II: effects of nucleotide binding on the stability of open states J. Gen. Physiol. 125 2005 377 394 Epub 2005 Mar 14
21. J.C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R.D. Skeel, L. Kale, and K. Schulten Scalable molecular dynamics with NAMD J. Comput. Chem. 26 2005 1781 1802
22. A.D. MacKerell Jr., D. Bashford, M. Bellott, R.L. Dunbrack Jr., J.D. Evanseck, M.J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, D. Joseph-McCarthy, L. Kuchnir, K. Kuczera, F.T.K. Lau, C. Mattos, S. Michnick, T. Ngo, D.T. Nguyen, B. Prodhom, W.E. Reiher III, B. Roux, M. Schlenkrich, J.C. Smith, R. Stote, J. Straub, M. Watanabe, J. Wiorkiewicz-Kuczera, D. Yin, and M. Karplus All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102 1998 3586 3616
23. N. Foloppe, and A. MacKerell Jr. All-atom empirical force field for nucleic Acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data J. Comput. Chem. 23 2000 123 199
24. W. Humphrey, A. Dalke, and K. Schulten VMD - visual molecular dynamics J. Mol. Graphics 14 1996 33 38
25. P.H. Thibodeau, C.A. Brautigam, M. Machius, and P.J. Thomas Side chain and backbone contributions of Phe508 to CFTR folding Nat. Struct. Mol. Biol. 12 2005 10 16
26. J. Ryckaert, A. Bellemans, G. Ciccotti, and G.V. Paolini Shear-rate dependence of the viscosity of simple fluids by nonequilibrium molecular dynamics Phys. Rev. Lett. 60 1988 128 131
27. U. Essmann, L. Perera, M. Berkowitz, T. Darden, H. Lee, and L. Pederson A smooth particle mesh Ewald method J. Chem. Phys. 103 1995 8577 8593
28. I. McDonald, and J. Thornton Satisfying hydrogen bonding potential in proteins J. Mol. Biol. 238 1994 777 793
29. J. Aqvist, V.B. Luzhkov, and B.O. Brandsdal Ligand binding affinities from MD simulations Acc. Chem. Res. 35 2002 358 365
30. W. Wang, J. Wang, and P.A. Kollman What determines the van der Waals coefficient beta in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations? Proteins 34 1999 395 402
31. P. Bisignano, and O. Moran Molecular dynamics analysis of the wild type and dF508 mutant structures of the human CFTR-nucleotide binding domain 1 Biochimie 92 2010 51 57
32. O. Moran, A. Grottesi, A.J. Chadburn, and P. Tammaro Parametrisation of the free energy of ATP binding to wild-type and mutant Kir6.2 potassium channels Biophys. Chem. 171 2013 76 83
33. M. Andér, V.B. Luzhkov, and J. Aqvist Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state-docking and computer simulations of a homology model Biophys. J. 94 2008 820 831
34. M. Almlof, B.O. Brandsdal, and J. Aqvist Binding affinity prediction with different force fields: examination of the linear interaction energy method J. Comput. Chem. 25 2004 1242 1254
35. Y. Norimatsu, A. Ivetac, C. Alexander, J. Kirkham, N. O'Donnell, D.C. Dawson, and M.S.P. Sansom Cystic fibrosis transmembrane conductance regulator: a molecular model defines the architecture of the anion conduction path and locates a "bottleneck" in the pore Biochemistry 51 2012 2199 2212
36. J. Dalton, O. Kalid, M. Schushan, N. Ben-Tal, and J. Villà-Freixa New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation J. Chem. Inf. Model. 52 2012 1842 1853
37. J. Carlsson, and J. Aqvist Calculations of solute and solvent entropies from molecular dynamics simulations Phys. Chem. Chem. Phys. 8 2006 5385 5395
38. P.A. Valiente, A. Gil, P.R. Batista, E.R. Caffarena, T. Pons, and P.G. Pascutti New parameterization approaches of the LIE method to improve free energy calculations of PlmII-Inhibitors complexes J. Comput. Chem. 31 2010 2723 2734
39. P. Vergani, A.C. Nairn, and D.C. Gadsby On the mechanism of MgATP-dependent gating of CFTR Cl- channels J. Gen. Physiol. 121 2003 17 36
40. P. Vergani, C. Basso, M. Mense, A.C. Nairn, and D.C. Gadsby Control of the CFTR channel's gates Biochem. Soc. Trans. 33 2005 1003 1007
41. M. Mense, P. Vergani, D.M. White, G. Altberg, A.C. Nairn, and D.C. Gadsby In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer EMBO J. 25 2006 4728 4739
42. R. Eudes, P. Lehn, C. Férec, J. Mornon, and I. Callebaut Nucleotide binding domains of human CFTR: a structural classification of critical residues and disease-causing mutations Cell. Mol. Life Sci. 62 2005 2112 2123
43. O. Moran, L.J.V. Galietta, and O. Zegarra-Moran Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains Cell. Mol. Life Sci. 62 2005 446 460
44. V.B. Luzhkov, and J. Aqvist Ions and blockers in potassium channels: insights from free energy simulations Biochim. Biophys. Acta 1747 2005 109 120
45. P. Kollman Free energy calculations: applications to chemical and biochemical phenomena Chem. Rev. 93 1993 2395 2417
46. R.J.P. Dawson, and K.P. Locher Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP FEBS Lett. 581 2007 935 938
47. R.J.P. Dawson, K. Hollenstein, and K.P. Locher Uptake or extrusion: crystal structures of full ABC transporters suggest a common mechanism Mol. Microbiol. 65 2007 250 257
48. F.G.D. Araújo, F.C. Novaes, N.P.C.D. Santos, V.C. Martins, S.M.D. Souza, S.E.B.D. Santos, and A.K.C. Ribeiro-dos-Santos Prevalence of deltaF508, G551D, G542X, and R553X mutations among cystic fibrosis patients in the North of Brazil Braz. J. Med. Biol. Res. 38 2005 11 15
49. B.W. Ramsey, J. Davies, N.G. McElvaney, E. Tullis, S.C. Bell, P. Dřevínek, M. Griese, E.F. McKone, C.E. Wainwright, M.W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S.M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordoñez, and J.S. Elborn A CFTR potentiator in patients with cystic fibrosis and the G551D mutation N. Engl. J. Med. 365 2011 1663 1672
50. F. Van Goor, S. Hadida, P.D.J. Grootenhuis, B. Burton, J.H. Stack, K.S. Straley, C.J. Decker, M. Miller, J. McCartney, E.R. Olson, J.J. Wine, R.A. Frizzell, M. Ashlock, and P.A. Negulescu Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc. Natl. Acad. Sci. U.S.A. 108 2011 18843 18848
51. M.P. Boyle, S.C. Bell, M.W. Konstan, S.A. McColley, S.M. Rowe, E. Rietschel, X. Huang, D. Waltz, N.R. Patel, and D. Rodman A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial Lancet Respir. Med. 2 2014 527 538
52. C. Alexander, A. Ivetac, X. Liu, Y. Norimatsu, J.R. Serrano, A. Landstrom, M. Sansom, and D.C. Dawson Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore Biochemistry 48 2009 10078 10088
53. A.W. Serohijos, T. Hegedus, J.R. Riordan, and N.V. Dokholyan Diminished self-chaperoning activity of the deltaF508 mutant of CFTR results in protein misfolding PLoS Comput. Biol. 4 2008 e1000008
54. T. Hegedus, A.W. Serohijos, N.V. Dokholyan, L. He, and J.R. Riordan Computational studies reveal phosphorylation-dependent changes in the unstructured R domain of CFTR J. Mol. Biol. 378 2008 1052 1063
55. P. Vergani, S.W. Lockless, A.C. Nairn, and D.C. Gadsby CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains Nature 433 2005 876 880